Thoracoscopic sympathotomy for palmar hyperhidrosis: How young is too young?
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Dec 2019 · 1 min read
In brief
In brief
Bilateral thoracoscopic sympathotomy effectively resolves palmar hyperhidrosis in pediatric patients (ages 11-19) with high satisfaction rates and no mortality. While compensatory sweating occurred in 48% of cases, all patients would recommend the procedure, with significant improvement in quality of life scores.
Written by the GCMD Library team from the article.
Abstract
Background/Purpose
Primary hyperhidrosis affects 1%–3% of the general population, with increased incidence in teenagers, having an important impact in the quality of life. This study evaluates the efficacy and patients' satisfaction after bilateral thoracoscopic sympathotomy.
Methods
Retrospective analysis of pediatric patients with palmar primary hyperhidrosis that underwent bilateral thoracoscopic sympathotomy over the last eight years. The procedure was performed with 2 ports and simple transection of the sympathetic chain. Pre and postoperative sweating severity was evaluated by telephone interview, using the Hyperhidrosis Disease Severity Scale (HDSS).
Results
23 patients (19 girls; 15.5 [11–19] years-old) underwent bilateral thoracoscopic sympathotomy. All complained of palmar hyperhidrosis, which resolved in all cases. Compensatory sweating occurred in 47.8% of patients. 21 patients answered the telephone interview: all of them would recommend the surgery to others. Sweating severity improved in all patients, with a mean decrease of 1.95 values of the HDSS from preoperative to postoperative evaluation (p < 0.05). There was neither morbidity nor mortality.
Conclusions
Bilateral thoracoscopic sympathotomy is a safe and effective treatment for primary palmar hyperhidrosis. Being the first report on pediatric application of HDSS, we conclude that children are very satisfied with the final outcome.
Type of study
Treatment study.
Level of evidence
Level III.